

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference		of Transmittal of International Search Report 20) as well as, where applicable, item 5 below.
45460-PT International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/CA 00/01153		
Applicant	03/10/2000	04/10/1999
Аррисан		
GAN, Zhibo		
This International Search Report has been according to Article 18. A copy is being tra	n prepared by this International Searching Authansmitted to the International Bureau.	nority and is transmitted to the applicant
This International Search Report consists  It is also accompanied by	of a total of3 sheets. a copy of each prior art document cited in this	report.
Basis of the report		
<ul> <li>a. With regard to the language, the language in which it was filed, unl</li> </ul>	international search was carried out on the basess otherwise indicated under this item.	sis of the international application in the
the international search w Authority (Rule 23.1(b)).	as carried out on the basis of a translation of the	he international application furnished to this
b. With regard to any nucleotide an was carried out on the basis of the contained in the internation		ternational application, the international search
	this Authority in written form.	
furnished subsequently to	this Authority in computer readble form.	
	sequently furnished written sequence listing disting disting disting distinct particular distributions of the sequence listing distributions are sequenced in the sequenced listing distributions are sequenced in the sequence listing distributions are sequenced in the sequenced listing distributions are sequenced in the sequenced listing distributions are sequenced in the sequenced listing are sequenced as a sequenced listing are sequenced listing and sequenced listing are sequenced as a sequenced are sequenced as a sequenced listing are sequenced as a sequenced as a sequenced are sequenced as a sequenced as a sequenced are sequenced as a sequenced are sequenced as a sequenced as a sequenced as a sequenced as a sequenced are sequenced as a sequenced a	oes not go beyond the disclosure in the
l		s identical to the written sequence listing has been
2. Certain claims were fou	nd unsearchable (See Box I).	
3. Unity of invention is lac	king (see Box II).	
4. With regard to the <b>title</b> ,		
X the text is approved as su	bmitted by the applicant.	
the text has been establis	hed by this Authority to read as follows:	
5. With regard to the abstract,		
The text is approved as su	bmitted by the applicant.	
the text has been establis	hed, according to Rule 38.2(b), by this Authorite date of mailing of this international search rep	ty as it appears in Box III. The applicant may, ort, submit comments to this Authority.
6. The figure of the <b>drawings</b> to be publ		<u></u>
as suggested by the appli	cant.	None of the figures.
because the applicant fail	ed to suggest a figure.	<del>_</del>
because this figure better	characterizes the invention.	

International Application No √CA 00/01153

A. CLASSIFICATION OF SUBJECT MATERIAL IPC 7 G01N33/543 G01N33/542

C12Q1/68

C12Q1/34

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 G01N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## EPO-Internal

C. DOCUME	ENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Χ	WO 96 25665 A (THE REGENTS OF THE UNIVERSITY OF CALIFORNIA) 22 August 1996 (1996-08-22)	1-9,11
Υ	the whole document	10,12-25
X	WO 98 39471 A (TROPIX, INC.) 11 September 1998 (1998-09-11) the whole document	12-25
Υ	WO 99 32655 A (NEN LIFE SCIENCE PRODUCTS, INC.) 1 July 1999 (1999-07-01) the whole document	1-25
Y	WO 96 08721 A (BIOCIRCUITS CORPORATION) 21 March 1996 (1996-03-21) the whole document/	1–25

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
Special categories of cited documents:      "A" document defining the general state of the art which is not considered to be of particular relevance      "E" earlier document but published on or after the international filing date      "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)      "O" document referring to an oral disclosure, use, exhibition or other means      "P" document published prior to the international filing date but later than the priority date claimed	<ul> <li>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</li> <li>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</li> <li>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</li> <li>"8" document member of the same patent family</li> </ul>
Date of the actual completion of the international search	Date of mailing of the international search report
20 February 2001	27/02/2001
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Griffith, G

International Application No
/CA 00/01153

	ation) DOCUMENTS CONSIDER TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 98 16657 A (CHIRON CORPORATION) 23 April 1998 (1998-04-23) the whole document	12-25
Y	EP 0 309 230 A (M.L. TECHNOLOGY VENTURES, L.P) 29 March 1989 (1989-03-29) abstract	10
Ą	WO 90 12888 A (BIOCONTROL SYSTEMS, INCORPORATED) 1 November 1990 (1990-11-01) the whole document	1-25
A	EP 0 244 932 A (BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM) 11 November 1987 (1987-11-11) the whole document	1-25
4	US 4 391 904 A (D. J. LITMAN ET AL.) 5 July 1983 (1983-07-05) the whole document	1-25
	<del></del>	
		!

information on patent family members

Patent document Publication Patent family Publication cited in search report member(s) date date WO 9625665 Α 22-08-1996 ΑU 13-01-2000 714839 B AU 04-09-1996 4982196 A CA 2211972 A 22-08-1996 EP 0809803 A 03-12-1997 JP 11500223 T 06-01-1999 US 6103217 A 15-08-2000 US 6080423 A 27-06-2000 WO 9839471 11-09-1998 6443498 A 22-09-1998 Α ΑU EP 0972071 A 19-01-2000 WO 9932655 01-07-1999 US 5972595 A Α 26-10-1999 ΑU 2000699 A 12-07-1999 EP 1042500 A 11-10-2000 US 6066446 A 23-05-2000 WO 9608721 Α 21-03-1996 CA 21-03-1996 2199149 A EP 0781413 A 02-07-1997 JP 10505904 T 09-06-1998 WO 9816657 Α 23-04-1998 ΑU 4904397 A 11-05-1998 29-03-1989 15-07-1995 EP 309230 Α AT 124143 T ΑU 633474 B 04-02-1993 AU 2554188 A 17-04-1989 CA 1339872 A 19-05-1998 27-07-1995 DE 3854029 D DE 3854029 T 26-10-1995 DK 244889 A 20-06-1989 EP 0638807 A 15-02-1995 ES 2074051 T 01-09-1995 FI 892435 A 19-05-1989 JP 2503147 T 04-10-1990 JP 2000350598 A 19-12-2000 JP 2000350599 A 19-12-2000 KR 9602561 B 22-02-1996 892043 A 17-07-1989 NO PT 31-07-1989 88562 A,B WO 8902476 A 23-03-1989 US 5639604 A 17-06-1997 US 5948899 A 07-09-1999 6004745 A 21-12-1999 US US 5283174 A 01-02-1994 WO 9012888 Α 01-11-1990 AU 639237 B 22-07-1993 ΑU 5655290 A 16-11-1990 CA 2062753 A 28-10-1990 DE 69020555 D 03-08-1995 DE 69020555 T 02-11-1995 EP 12-02-1992 0470172 A JP 3043063 B 22-05-2000 JP 4504802 T 27-08-1992 04-04-1995 US 5403721 A EP 244932 Α 11-11-1987 US 4859581 A 22-08-1989 ΑU 609386 B 02-05-1991 17-09-1987 6987087 A ΑU 04-12-1987 DK 122087 A

International Application No

/CA 00/01153

Information on patent family members

International Application No
/CA 00/01153

	<del></del>		·				00/01155
	document earch report		Publication date		Patent family member(s)		Publication date
EP 24	4932	Α		FI	871039	Α	11-09-1987
				FI	924243	Α	22-09-1992
				FI	924244	Α	22-09-1992
				NO	870977	Α	11-09-1987
				NO	930635	Α	11-09-1987
				US	5332812	Α	26-07-1994
				JP	62265998	Α	18-11-1987
				US	5262403	Α	16-11-1993
US 43	 91904	Α	05-07-1983	US	4299916	Α	10-11-1981
				US	5342759	Α	30-08-1994
				US	4533629	Α	06-08-1985
				US	4540659	Α	10-09-1985
	•			US	5432057	Α	11-07-1995
				AU	538687	В	23-08-1984
				AU	6132080		02-07-1981
				BR	8007330		30-06-1981
				CA	1138332		28-12-1982
				DE	3071340		20-02-1986
				EP	0032286		22-07-1981
				ES	495936		16-01-1982
				ES	8202364		16-04-1982
				IL	60817		29-02-1984
				JP	1030109		16-06-1989
				JP	1548194		09-03-1990
				JP	61269068		28-11-1986
				JP	1465415	_	10-11-1988
				JP	56092218		25-07-1981
				JP	63012260		18-03-1988
				MX	6798		25-07-1986
				US	5156953		20-10-1992
				US	4843000	A	27-06-1989

### PATENT COOPERATION TREATY

From the INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

GALE, Edwin J. et al. KIRBY EADES GALE BAKER Box 3432, Station D Ottawa, Ontario K1P 6N9 CANADA



NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing (day/month/year)

23.01.2002

Applicant's or agent's file reference 45460-PT

International application No. PCT/CA00/01153

International filing date (day/month/year)

03/10/2000

Priority date (day/month/year)

IMPORTANT NOTIFICATION

04/10/1999

Applicant

GAN, Zhibo

- 1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
- 2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- 3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

#### 4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/

European Patent Office D-80298 Munich

Tel. +49 89 2399 - 0 Tx: 523656 pmu d

Fax: +49 89 2399 - 4465

Authorized officer

Danti, B

Tel.+49 89 2399-8161





# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference		O Nigo A STransauli of his mall and		
45460-PT	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)		
International application No.	International filing date (day/month	/year) Priority date (day/month/year)		
PCT/CA00/01153	03/10/2000	04/10/1999		
International Patent Classification (IPC) or na G01N33/543	ational classification and IPC			
Applicant				
GAN, Zhibo				
This international preliminary exam and is transmitted to the applicant a		by this International Preliminary Examining Authority		
2. This REPORT consists of a total of	5 sheets, including this cover sh	eet.		
been amended and are the bas (see Rule 70.16 and Section 60	sis for this report and/or sheets or 07 of the Administrative Instruction	e description, claims and/or drawings which hav ontaining rectifications made before this Authority ons under the PCT).		
These annexes consist of a total of	2 sneets.	· R-		
3. This report contains indications rela	ting to the following items:			
Basis of the report	<u> </u>			
II □ Priority				
III   Non-establishment of o	pinion with regard to novelty, inve	entive step and industrial applicability		
IV  Lack of unity of invention	n ·			
V 🛛 Reasoned statement ur citations and explanation	nder Article 35(2) with regard to none suporting such statement	ovelty, inventive step or industrial applicability;		
VI   Certain documents cite	ed .			
VII Certain defects in the in	ternational application			
VIII 🛛 Certain observations on	the international application	·		
Date of submission of the demand	Date of co	ompletion of this report		
02/05/2001	23.01.20	02		
Name and mailing address of the International Authorized officer				
preliminary examining authority:				
European Patent Office D-80298 Munich	Linker,	₩ ( <u>@</u> <b>②))</b>		
Tel. +49 89 2399 - 0 Tx: 523656 Fax: +49 89 2399 - 4465	epmu d	No. +49.89 2399 8703		

International application No. PCT/CA00/01153

language in which the international application was filed, unless otherwise indicated under this item.  These elements were available or furnished to this Authority in the following language: , which is:  the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).  the language of publication of the international application (under Rule 48.3(b)).  the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).  With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:  contained in the international application in written form.  filed together with the international application in computer readable form.  furnished subsequently to this Authority in computer readable form.  The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.  The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.  The amendments have resulted in the cancellation of:  the description, pages:  the claims, Nos.:							,
the receiving Office in response to an invitation under Article 14 are referred to in this report as 'originally filed" and are not annexed to this report since they do not contain amendments (Fules 70.16 and 70.17)):  Description, pages:  1,2,4-9	I.	Ва	sis of th report				
Claims, No.:  1-25 as originally filed  2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.  These elements were available or furnished to this Authority in the following language: , which is:  the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).  the language of publication of the international application (under Rule 48.3(b)).  the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).  3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:  contained in the international application in written form.  filed together with the international application in computer readable form.  furnished subsequently to this Authority in computer readable form.  furnished subsequently to this Authority in computer readable form.  The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.  The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.  The amendments have resulted in the cancellation of:  the description, pages: the claims, Nos.:	1.	the an	e receiving Office in d are not annexed t	response to an invitation under	Article 14 are	referred to in this rep	oort as "originally filed"
Claims, No.:  1-25 as originally filed  2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.  These elements were available or furnished to this Authority in the following language: , which is:  the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).  the language of publication of the International application (under Rule 48.3(b)).  the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).  3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:  contained in the international application in written form.  filed together with the international application in computer readable form.  turnished subsequently to this Authority in written form.  The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.  The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.  The amendments have resulted in the cancellation of:  the description, pages:  the claims, Nos.:		1,2	2,4-9	as originally filed			
2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.  These elements were available or furnished to this Authority in the following language: , which is:    the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).   the language of publication of the international application (under Rule 48.3(b)).   the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).  3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:    contained in the international application in written form.   filed together with the international application in computer readable form.   furnished subsequently to this Authority in written form.   furnished subsequently to this Authority in computer readable form.   The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.   The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.   The amendments have resulted in the cancellation of:   the description, pages:   the claims, Nos.:		3,3	<b>3a</b>	as received on	20/12/2001	with letter of	14/12/2001
2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.  These elements were available or furnished to this Authority in the following language: , which is:  the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).  the language of publication of the international application (under Rule 48.3(b)).  the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).  With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:  contained in the international application in written form.  filed together with the international application in computer readable form.  furnished subsequently to this Authority in written form.  the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.  The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.  The amendments have resulted in the cancellation of:  the description, pages:  the claims, Nos.:		Cla	aims, No.:	,			
language in which the international application was filed, unless otherwise indicated under this item.  These elements were available or furnished to this Authority in the following language: , which is:  the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).  the language of publication of the international application (under Rule 48.3(b)).  the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).  With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:  contained in the international application in written form.  filed together with the international application in computer readable form.  furnished subsequently to this Authority in computer readable form.  The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.  The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.  The amendments have resulted in the cancellation of:  the description, pages:  the claims, Nos.:		1-2	25	as originally filed			
These elements were available or furnished to this Authority in the following language: , which is:  the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).  the language of publication of the international application (under Rule 48.3(b)).  the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).  With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:  contained in the international application in written form.  filed together with the international application in computer readable form.  furnished subsequently to this Authority in written form.  furnished subsequently to this Authority in computer readable form.  The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.  The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.  The amendments have resulted in the cancellation of:  the description, pages:  the claims, Nos.:						ú.	
the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).  the language of publication of the international application (under Rule 48.3(b)).  the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).  With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:  contained in the international application in written form.  filed together with the international application in computer readable form.  furnished subsequently to this Authority in written form.  furnished subsequently to this Authority in computer readable form.  The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.  The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.  The amendments have resulted in the cancellation of:  the description, pages:  the claims, Nos.:	2.						
the language of publication of the international application (under Rule 48.3(b)).  the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).  With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:  contained in the international application in written form.  filed together with the international application in computer readable form.  furnished subsequently to this Authority in written form.  furnished subsequently to this Authority in computer readable form.  The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.  The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.  The amendments have resulted in the cancellation of:  the description, pages:  the claims, Nos.:		The	ese elements were a	available or furnished to this Au	thority in the fo	ollowing language:	, which is:
international preliminary examination was carried out on the basis of the sequence listing:  contained in the international application in written form.  filed together with the international application in computer readable form.  furnished subsequently to this Authority in written form.  furnished subsequently to this Authority in computer readable form.  The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.  The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.  The amendments have resulted in the cancellation of:  the description, pages:  the claims, Nos.:			the language of pu	ublication of the international ap	plication (und	er Rule 48.3(b)).	
<ul> <li>☐ filed together with the international application in computer readable form.</li> <li>☐ furnished subsequently to this Authority in computer readable form.</li> <li>☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.</li> <li>☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.</li> <li>The amendments have resulted in the cancellation of:</li> <li>☐ the description, pages:</li> <li>☐ the claims, Nos.:</li> </ul>	3.						
<ul> <li>☐ filed together with the international application in computer readable form.</li> <li>☐ furnished subsequently to this Authority in computer readable form.</li> <li>☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.</li> <li>☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.</li> <li>∴ The amendments have resulted in the cancellation of:</li> <li>☐ the description, pages:</li> <li>☐ the claims, Nos.:</li> </ul>			contained in the in	ternational application in writter	form.	•	
<ul> <li>☐ furnished subsequently to this Authority in written form.</li> <li>☐ furnished subsequently to this Authority in computer readable form.</li> <li>☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.</li> <li>☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.</li> <li>The amendments have resulted in the cancellation of:</li> <li>☐ the description, pages:</li> <li>☐ the claims, Nos.:</li> </ul>		_				able form.	
<ul> <li>☐ furnished subsequently to this Authority in computer readable form.</li> <li>☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.</li> <li>☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.</li> <li>☐ The amendments have resulted in the cancellation of:</li> <li>☐ the description, pages:</li> <li>☐ the claims, Nos.:</li> </ul>			· -	• •	•		· .
<ul> <li>□ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.</li> <li>□ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.</li> <li>∴ The amendments have resulted in the cancellation of:</li> <li>□ the description, pages:</li> <li>□ the claims, Nos.:</li> </ul>			•	·		orm.	
listing has been furnished.  The amendments have resulted in the cancellation of:  □ the description, pages: □ the claims, Nos.:			The statement that	the subsequently furnished wr	itten sequence		peyond the disclosure i
☐ the description, pages: ☐ the claims, Nos.:					mputer readal	ole form is identical to	the written sequence
☐ the claims, Nos.:	•	The	amendments have	resulted in the cancellation of:		•	
☐ the claims, Nos.:			the description.	pages:			
		_	•	. •			
		_	the drawings,	sheets:			

5. 🗆	This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):	
		(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

- 6. Additional observations, if necessary:
- V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

12-18, 22, 24, 25

1. Statement

Novelty (N)

Yes: No:

Claims

Claims 1-11, 19-21, 23

Inventive step (IS)

Yes:

Claims 1-11

No:

Claims 12-25

Industrial applicability (IA)

Yes:

Claims 1-25

No:

Claims

2. Citations and explanations see separate sheet

#### VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

separate sheet

## Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following documents:

D1: WO 99 32655 A (NEN LIFE SCIENCE PRODUCTS, INC.) 1 July 1999 (1999-07-01)

D2: WO 98 16657 A (CHIRON CORPORATION) 23 April 1998 (1998-04-23)

The subject-matter of present claims 12-15 and 24 is already known from document D1, see in particular page 3, lines 6-15, 21 and 24, page 5, lines 5, 15-17 and 23, page 6. lines 1, 8, and 14-24, page 7, lines 1-7 and 12-14. Furthermore, the subject-matter of claims 12-18, 22, 24 and 25 is already known from document D2, see in particular page 2, lines 10-20, page 6, lines 14-16 and 18, page 7, line 6, page 8, line 10 and 14. page 9. lines 3-7. Thus, the present application does not satisfy the criterion set forth in Article 33(2) PCT because the subject-matter of claims 12-18, 22, 24 and 25 is not novel (or inventive according to Article 33(3) PCT).

While the applicant's observations have been considered, the previously expressed opinion is nevertheless maintained for the following reason:

The Applicant has pointed to differences between the prior art and the present invention, however, the wording of the aforementioned claims is such that the claimed subject-matter cannot be distinguished from the above state of the art.

Using respective substrates for the enzymes selected according to dependent claims 19-21 and 23 is not considered to involve an inventive step as the skilled person could expect that the method of D2 can also be applied to enzyme/substrate combinations different from those explicitly mentioned in D2.

The subject-matter of claims 1-11 appears not to be disclosed or suggested by any of the cited prior art documents, thus, the subject-matter of claims 1-11 appears to satisfy the criterions set forth in Article 33(2) and (3) PCT.

# R Item VIII

## Certain observations on the international application

The features mentioned on page 3, lines 22-24 (i.e. due to the uneven distribution of the label between surface and liquid in a vessel after completion of the reaction) and page 4, lines 3-4 (i.e. without an additional step) appear to be essential to the claimed method in view of the object indicated on page 3, lines 4-5. Thus, claims 1, 12 and 25 do not satisfy the criterion set forth in Article 6 PCT.

5

10

15

20

25

3

catalytic activity of an enzyme and not just the amount of the enzyme as a given amount of the enzyme may have a widely varying activity depending on reaction conditions.

International PCT Application No. WO 99/32655 filed in the name of Nen Life Science Products, Inc. of Boston, Massachusetts, USA, published on July 1<sup>st</sup>, 1999, relates to a method for analyzing a sample for the presence and/or activity of an enzyme. The invention makes use of a hydrophobic layer formed on a solid support, the hydrophobic layer incorporating by hydrophobic interactions and amphipathic enzyme substrate labeled with a reporter on its hydrophilic region. The hydrophobic material having the substrate disposed therein is contacted with a sample and with a polar solvent, whereby enzyme present in the sample cleaves the substrate and produces a labeled hydrophilic fragment, which fragment migrates to the polar solvent. The presence of the reporter is then detected in the polar solvent or in the hydrophobic layer.

International PCT Application No. WO 98/16657 filed in the name of Chiron Corporation of Emeryville, California, USA, which was published on April 23<sup>rd</sup>, 1998, relates to a method of screening a compound capable of regulating protease activity by incubating a protease and a polypeptide in the presence and absence of a test compound. The polypeptide comprises an anchor region, a protease recognition site and a detectable signal region. The anchor region is bound to a solid support and the protease recognition site comprises (a) a protease cleavable peptide bond, and (b) at least three naturally adjacent amino acids on each side of the cleavable peptide bond. The signal region bound to the solid support is detected. Detecting an amount of the signal region bound to the solid support in the presence of the test compound, which is greater or smaller than an amount detected in the absence of the test compound, indicates that the test compound is capable of regulating protease activity.

It is important for developing a method to reduce the step of the measurement procedure.

10

### DISCLOSURE OF THE INVENTION


This present invention is for a method referred to as non-separation heterogeneous assay that greatly simplifies the detection, identification, measurement of concentration and activity of biological substances. It is based on the change of the label signal due to the distribution of the label between a solid surface and liquid in a vessel after completion of the reaction among reactants. The method involves the coating of a reactant (labeled or unlabeled) onto a surface, addition of a sample with or without a competitor labeled using a label tag or unlabelled. The change of the label signal can be directly measured.

#### DETAILED DESCRIPTION OF THE INVENTION

- The present invention relates to a new method for the detection, identification, measurement of concentration and activity of biological substances, which is based on the change of the label signal due to the uneven distribution of the label between surface and liquid in a vessel after completion of the reaction among reactants.
- 20 1. An assay in which the surface of a vessel is coated with reactant 1 which is a binding ligand for reactant 3 being the labeled form of reactant 2. Competitive binding reactions between reactant 2 and reactant 3 for reactant 1 or between reactant

# PATENT COOPERATION TREATY





# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

		ent's file reference	FOR FURTHER ACTION	241	rication of Transmittal of International ary Examination Report (Form PCT/IPEA/416)
45460-P					· · · · · · · · · · · · · · · · · · ·
Internation			International filing date (day/i	nonth/year)	Priority date (day/month/year)
PCT/CA			03/10/2000	-, ,	04/10/1999
Internation G01N33		ent Classification (IPC) or na	tional classification and IPC		
Applicant					
GAN, Zh	ibo				
		ational preliminary exam smitted to the applicant a		pared by this Int	ternational Preliminary Examining Authority
2. This	REPC	ORT consists of a total of	5 sheets, including this cov	ver sheet.	
b (s	seen a	amended and are the bas	sis for this report and/or she 07 of the Administrative Inst	ets containing r	on, claims and/or drawings which have rectifications made before this Authority the PCT).
3. This r	report	contains indications rela	iting to the following items:		
1	$\boxtimes$	Basis of the report			
II		Priority			
III		Non-establishment of o	pinion with regard to novelty	y, inventive ster	o and industrial applicability
IV		Lack of unity of invention	n		
V	×	Reasoned statement un citations and explanation	nder Article 35(2) with regar	d to novelty, inv	ventive step or industrial applicability;
VI		Certain documents cite			
VII	_	Certain defects in the ir			
VIII			n the international applicatio	n	
<u>.                                    </u>		·			•
Date of sub	omissio	on of the demand	Da	te of completion o	of this report
02/05/20	01		23.	01.2002	
	exami	g address of the internationa ining authority:	I Au	thorized officer	SEAR SOES MICHORAL
<u>)</u>	D-80 Tel.	opean Patent Office 0298 Munich +49 89 2399 - 0 Tx: 523656 : +49 89 2399 - 4465	S epmu d	nker, W	The state of the s
	rax.	+49 69 2399 - 4465	Tet	ephone No. +49 8	39 2399 8703



l. Basis	of the	report
----------	--------	--------

	and	_	response to an invitation u o this report since they do l			• • • •
	1,2	,4-9	as originally filed			
	3,3	a	as received on	20/12/2001	with letter of	14/12/2001
	Cla	ims, No.:				
	1-2	5	as originally filed			
2.			guage, all the elements ma international application wa			
	The	ese elements were a	available or furnished to thi	is Authority in the fo	ollowing language:	, which is:
			translation furnished for the			(under Rule 23.1(b)).
		the language of pu	ublication of the internation	al application (unde	er Rule 48.3(b)).	
		the language of a 55.2 and/or 55.3).	translation furnished for the	e purposes of inter	national preliminar	y examination (under Rule
3.			cleotide and/or amino aciony examination was carried			
		contained in the in	ternational application in w	vritten form.		
		filed together with	the international applicatio	n in computer read	able form.	
		furnished subsequ	ently to this Authority in wr	ritten form.		
		furnished subsequ	ently to this Authority in co	omputer readable fo	orm.	
			t the subsequently furnishe pplication as filed has beer		e listing does not g	o beyond the disclosure in
		The statement tha listing has been fu	t the information recorded rnished.	in computer readat	ole form is identical	to the written sequence
1.	The	e amendments have	e resulted in the cancellatio	on of:		
		the description,	pages:			
		the claims,	Nos.:			
		the drawings,	sheets:			

1. With regard to the elements of the international application (Replacement sheets which have been furnished to



5. C	This report has been established as if (some of) the amendments had not been made, since they have been
	considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes:

Claims 1-11, 19-21, 23

Inventive step (IS)

No: Yes: Claims 12-18, 22, 24, 25

No:

No:

Claims 1-11 Claims 12-25

Industrial applicability (IA)

Yes: Claims 1-25

Claims

2. Citations and explanations see separate sheet

#### VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made: see separate sheet

## R Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following documents:

D1: WO 99 32655 A (NEN LIFE SCIENCE PRODUCTS, INC.) 1 July 1999 (1999-07-01)

D2: WO 98 16657 A (CHIRON CORPORATION) 23 April 1998 (1998-04-23)

The subject-matter of present claims 12-15 and 24 is already known from document D1, see in particular page 3, lines 6-15, 21 and 24, page 5, lines 5, 15-17 and 23, page 6, lines 1, 8, and 14-24, page 7, lines 1-7 and 12-14. Furthermore, the subject-matter of claims 12-18, 22, 24 and 25 is already known from document D2, see in particular page 2, lines 10-20, page 6, lines 14-16 and 18, page 7, line 6, page 8, line 10 and 14, page 9, lines 3-7. Thus, the present application does not satisfy the criterion set forth in Article 33(2) PCT because the subject-matter of claims 12-18, 22, 24 and 25 is not novel (or inventive according to Article 33(3) PCT).

While the applicant's observations have been considered, the previously expressed opinion is nevertheless maintained for the following reason:

The Applicant has pointed to differences between the prior art and the present invention, however, the wording of the aforementioned claims is such that the claimed subject-matter cannot be distinguished from the above state of the art.

Using respective substrates for the enzymes selected according to dependent claims 19-21 and 23 is not considered to involve an inventive step as the skilled person could expect that the method of D2 can also be applied to enzyme/substrate combinations different from those explicitly mentioned in D2.

The subject-matter of claims 1-11 appears not to be disclosed or suggested by any of the cited prior art documents, thus, the subject-matter of claims 1-11 appears to satisfy the criterions set forth in Article 33(2) and (3) PCT.

## Re It m VIII

## Certain observations on the international application

The features mentioned on page 3, lines 22-24 (i.e. due to the uneven distribution of the label between surface and liquid in a vessel after completion of the reaction) and page 4, lines 3-4 (i.e. without an additional step) appear to be essential to the claimed method in view of the object indicated on page 3, lines 4-5. Thus, claims 1, 12 and 25 do not satisfy the criterion set forth in Article 6 PCT.

péplace 34 Nt. by artisme WO 01/25788

10

15

catalytic activity of an enzyme and not just the amount of the enzyme as a given amount of the enzyme may have a widely varying activity depending on reaction conditions.

It is important for developing a method to reduce the step of the measurement procedure.

#### DISCLOSURE OF THE INVENTION -----

This present invention is for a method referred to as non-separation heterogenous assay that greatly simplifies the detection, identification, measurement of concentration and activity of biological substances. It is based on the change of the label signal due to the distribution of the label between a solid surface and liquid in a vessel after completion of the reaction among reactants. The method involves the coating of a reactant (labeled or unlabeled) onto a surface, addition of a sample with or without a competitor labeled using a label tag or unlabeled. The change of the label signal can be directly measured.

## DETAILED DESCRIPTION OF THE INVENTION

- The present invention relates to a new method for the detection, identification, measurement of concentration and activity of biological substances, which is based on the change of the label signal due to the uneven distribution of the label between surface and liquid in a vessel after completion of the reaction among reactants.
- 25 1. An assay in which the surface of a vessel is coated with reactant 1 which is a binding ligand for reactant 3 being the labeled form of reactant 2. Competitive binding reactions between reactant 2 and reactant 3 for reactant 1 or between reactant